BriaCell Therapeutics Corp Ordinary Shares BCTX 深 沪
等待开盘 10-17 09:30:00 美东时间
12.32
+0.600
+5.12%
华盛通- 最 高12.76
- 今 开11.94
- 成交量 5.46万股
- 最 低 11.80
- 昨 收 11.72
- 总市值 8348.16万
- 52周最高 190.50
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 6.00
- 委 比 -29.87%
- 总股本 677.61万
- 历史最高 1860.5799
- 量 比 0.73
- 振 幅 8.19%
- 历史最低 11.80
- 每 手 1
- 风险率 40.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell to Present Phase 3 Biomarker Data for Bria-IMT in Metastatic Breast Cancer at ESMO 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be presenting
10-13 19:34
BriaCell Therapeutics To Present Preclinical Bria-OTS+ Data At SITC Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
10-03 19:37
HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Raises Price Target to $40
HC Wainwright & Co. analyst Emily Bodnar maintains BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and raises the price target from $32 to $40.
08-27 18:12
BriaCell Publishes Breakthrough Cancer Immunotherapy Research In JCI Insight Journal
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the
08-26 19:35
BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
BriaCell Therapeutics announced the publication of their Bria-OTS+ platform's mechanism of action in JCI Insight. The study, conducted with the US National Cancer Institute, shows that Bria-OTS+ enhances anti-tumor responses by leveraging semi-allogeneic dendritic cells and Treg depletion. The platform, designed for personalized off-the-shelf cancer immunotherapy, is currently in a Phase 1/2a trial for metastatic breast cancer, with promising cli...
08-26 11:30
BriaCell Announces 1-for-10 Share Consolidation To Maintain Nasdaq Listing, Effective August 25, 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that
08-22 00:02
BriaCell Joins MSK's 2025 Therapeutics Accelerator to Fast-Track Cancer Immunotherapy
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
08-13 19:36
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
BriaCell Therapeutics Corp. announced its acceptance into Memorial Sloan Kettering Cancer Center’s 2025 Therapeutics Accelerator program to accelerate the clinical development of its Bria-OTS+ immunotherapy for multiple cancers, including breast and prostate cancer. MSK’s resources will support regulatory and manufacturing efforts, with both parties expressing confidence in the therapy’s potential to advance cancer care.
08-13 11:30
BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics Corp. announced the consolidation of its common shares on a 1:10 basis to maintain compliance with Nasdaq listing requirements. The consolidation, subject to TSX and Nasdaq approval, is expected to take effect on August 25, 2025, with post-consolidation shares trading starting on August 26. Fractional shares will be rounded up or canceled, and outstanding convertible securities will be adjusted proportionally. Post-consolida...
08-06 00:17
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Therapeutics has added UCLA Health Jonsson Comprehensive Cancer Center to its Phase 3 trial evaluating the Bria-IMT therapy in combination with a checkpoint inhibitor for advanced metastatic breast cancer. The trial compares this regimen with physician's choice. Interim analysis will assess 144 patient events, with overall survival as the primary endpoint. The trial builds on Phase 2 data showing promising survival outcomes and has recei...
07-31 11:30
